MAM
“King’s Love” Korean Drama to Rule India
MUMBAI: One Take Media Co. is known for its variety in the Content Market. Hence, with the increasing demand of Korean Content in India, One Take Media Co. is focused in building its Korean Content library day by day. OTMC has not only acquired a lot of Korean Dramas Series but has also taken an intelligent move by dubbing all of its Korean Dramas in Hindi. This will result in bringing a new target audience to join the club of Korean Wave. Along with Korean Drama Series, OTMC also caters in Korean Pop commonly known as K-POP.
One Take Media Co. is happy to introduce you to its recent acquisition of a historic romance drama series, Kings Love. Kings Love is a 2017, 20 episodes Korean Drama featuring Se-ha Ahn, Jong-hwan Choi and Soo-Hyun Choo.
Kings Loveis about a story of a young and ambitious monarch Won (Im Si-wan), and two people who shaped his destiny; childhood friend Wang Rin (Hong Jong-hyun) and a beautiful young woman named San (Im Yoon-ah). These three get to know each other and become the closest of friends but feelings of affection and love arise between these three. The young Crown Prince, falls in love with the young woman San and would do anything to save her. He comes to love her more than himself. But on the other hand, is his childhood friend Wang Rin who also fell in love with San at first sight. Even though he loves her so much, he still hid his affection for her because of his duty to his Crown Prince and because he doesn't want to hurt his best friend's feelings. But the time came when San realizes her feelings for Rin and vice versa.
The Satellite TV/OTT/VOD rights for Kings Love are available with One Take Media Co. This Drama Series is available for SAARC Region.
One Take Media Co. is a global Content Production and Distribution company. With more than 10,000 hours of varied content, OTMC caters its services in many genres like Hollywood Movies dubbed in more than 9 regional languages, Kids Animation content, Cooking Content, Korean Content, Music and Web Series.
Mr. Anil Khera, Founder and CEO of One Take Media Co. said, “The Culture of India and Korea is very similar. And that is the reason, I am confident about the content doing great in the Indian Market. And dubbing it in Hindi is helping us to cater a larger audience."
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
